Terumo Corporation
30-Second Executive Brief
Executive Assessment
Terumo Corporation functions as a regional institution within Healthcare & Life Sciences, backed by 47% sourcing coverage, with accelerating strategic relevance.
- Maintains 3 mapped relationships across the graph
- 47% sourcing coverage across sourced relationships
- Tracked as regional institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Regional Institution
- Sourcing Coverage
- 47%
- Ecosystem Influence
- Moderate
- Strategic Momentum
- Accelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 3
- Technology Domains
- 5
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
A Japanese medical device company spanning cardiovascular, blood management, and general hospital products, reporting FY2026 (fiscal year ended March 2026) revenue of ¥1.13 trillion (up 9.2%) with operating profit up 11.8% and profit attributable to owners up 16.2%. Terumo's Q1 FY2027 revenue (three months to June 2026) surged 19.9% to ¥311.8 billion, and the company launched its TR Band Distal hemostasis device in Japan and began the pivotal IDE study for its Rapidlink aortic device in the US and Europe, guiding to 9% full-year revenue growth and a 20% operating margin target.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source
- TipRanks — Terumo delivers double-digit profit growth and raises dividend on robust FY2026 resultsnews
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Terumo Corporation — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
Terumo's headline growth numbers likely overstate underlying constant-currency momentum
29% confidenceTerumo reported FY2026 revenue up 9.2% and Q1 FY2027 revenue surging 19.9%, but the company itself flags that a meaningful portion of this growth is FX-assisted, with guidance for 9% full-year growth and a 20% operating margin resting on organic execution rather than acquisitions.
This is InsightNodes' own interpretive read: when a company explicitly notes FX assistance in its own results, the more conservative reading is that underlying constant-currency growth is running below the reported headline figures -- the Q1 FY2027 19.9% jump in particular should be treated cautiously until a constant-currency breakdown is available, since yen volatility can swing reported figures substantially without reflecting genuine changes in device demand or pricing power.
InsightNodes analysis of Terumo's FY2026 currency-adjusted growth · Aug 14, 2026
Terumo Corporation's Timeline
A sourced, dated history of Terumo Corporation's key moments — founding to present.
Jan 2026 · Launches Rapidlink pivotal IDE study
Terumo Aortic launched the Rapidlink pivotal IDE study in the United States and Europe, advancing its aortic device pipeline.
Jun 2026 · FY2026 results: revenue up 9.2%, profit up 16.2%
Terumo reported fiscal year 2026 (ended March 2026) revenue of ¥1.13 trillion, up 9.2%, with operating profit up 11.8% and profit attributable to owners up 16.2%.